Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB006 in Acute Ischemic Stroke
NCT05156827Phase 2Withdrawn
- Sponsor
- TrueBinding Inc.
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing TB006 with Placebo (2 arms). Primary endpoint: Percentage of Participants with Recovery Success Measured by modified Rankin Scale (mRS) score of 0-1 at Day 90. Planned start Jul 2022; status: withdrawn.
02
Drugs
TB006
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05156827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156827.